# Eli Lilly's Indian market share fell to 56% in March from 61% a month earlier.

*business · news · 2026-04-10 · CNBC*

## Key points

- Eli Lilly's GLP-1 market share in India fell from 61% to 56% in March 2024.
- Thirteen Indian generic companies launched 26 semaglutide brands within weeks of patent expiry.
- Novo Nordisk cut Ozempic and Wegovy prices by 38% and 48% respectively in India.
- Some Indian generic semaglutide versions are priced as low as 1,290 rupees per month.
- India's GLP-1 market is projected to grow nearly five-fold to 50 billion rupees by 2030.

**Companies:** Eli Lilly, Novo Nordisk, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Dr. Reddy's Laboratories, Zydus Lifesciences
**Countries:** India, Denmark

[Read the full story on CNBC](https://www.cnbc.com/2026/04/10/eli-lilly-slips-novo-nordisk-holds-firm-as-generic-weight-loss-drugs-flood-india.html)

---

Canonical: https://newsio.io/n/038a6cea-baf7-4fc3-b9c4-08b722cffd64/eli-lillys-indian-market-share-fell-to-56-in-march-from-61-a-month-earlier
Summarized by Newsio from CNBC. https://newsio.io/how-it-works